Burzynski Research Institute, Inc. (BZYR)
Nur zu Informationszwecken. Keine Finanzberatung. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Burzynski Research Institute, Inc. (BZYR) ist im Healthcare-Sektor taetig, zuletzt notiert bei $ mit einer Marktkapitalisierung von 0. Bewertet mit 42/100 (vorsichtig) bei Wachstumspotenzial, finanzieller Gesundheit und Momentum.
Zuletzt analysiert: 15. März 2026Burzynski Research Institute, Inc. (BZYR) Gesundheitswesen & Pipeline-Uebersicht
Burzynski Research Institute, Inc., founded in 1977, is a biotechnology company focused on researching, developing, and marketing antineoplaston drugs for cancer treatment. Operating in the competitive healthcare sector, the company also provides consulting services and produces medical chemical compounds under the Antineoplastons trade name.
Investmentthese
Investing in Burzynski Research Institute, Inc. (BZYR) presents a speculative opportunity due to its focus on antineoplaston drugs, a novel approach to cancer treatment. The company's potential value drivers include successful clinical trials and regulatory approvals for its Antineoplastons. However, the company's negative P/E ratio of -2.55 indicates it is not currently profitable. Key risks include the uncertainty of regulatory approval, competition from established cancer therapies, and the challenges of operating in the OTC market. The company's low beta of 0.28 suggests lower volatility compared to the broader market, but this may also reflect limited trading activity.
Basierend auf FMP-Finanzdaten und quantitativer Analyse
Wichtige Highlights
- Market capitalization of $0.00B indicates a micro-cap company with limited financial resources.
- Negative P/E ratio of -2.55 reflects the company's current lack of profitability.
- Beta of 0.28 suggests lower volatility compared to the overall market.
- Focus on antineoplaston drugs represents a unique approach to cancer treatment.
- The company's operations include research, development, production, marketing, and consulting services.
Wettbewerber & Vergleichsunternehmen
Staerken
- Unique antineoplaston therapies.
- Experienced leadership in cancer research.
- Established brand name (Antineoplastons).
- Dedicated focus on alternative cancer treatments.
Schwaechen
- Limited financial resources.
- Dependence on a single product line.
- Lack of profitability (negative P/E ratio).
- OTC market listing (lower liquidity and visibility).
Katalysatoren
- Upcoming: Results from ongoing clinical trials of Antineoplastons for various cancer types.
- Ongoing: Potential for strategic partnerships with larger pharmaceutical companies.
- Upcoming: Regulatory submissions for Antineoplastons in new geographic markets.
- Ongoing: Development of new antineoplaston formulations.
- Ongoing: Expansion of consulting services related to antineoplaston therapies.
Risiken
- Potential: Competition from established cancer therapies and larger pharmaceutical companies.
- Ongoing: Regulatory hurdles and uncertainty surrounding the approval of Antineoplastons.
- Potential: Adverse results from clinical trials of Antineoplastons.
- Ongoing: Limited financial resources and dependence on a single product line.
- Ongoing: OTC market listing and associated risks (low liquidity, limited disclosure).
Wachstumschancen
- Expansion of Clinical Trials: Burzynski Research Institute has the opportunity to expand its clinical trials to new cancer types and patient populations. Positive results from these trials could lead to increased interest in its Antineoplastons and potential regulatory approvals. The global oncology market is projected to reach $286.6 billion by 2030, providing a substantial market for successful cancer therapies. Timeline: Ongoing.
- Strategic Partnerships: Forming strategic partnerships with larger pharmaceutical companies or research institutions could provide Burzynski Research Institute with access to additional funding, expertise, and resources. Collaborations could accelerate the development and commercialization of its Antineoplastons. The pharmaceutical industry is increasingly reliant on partnerships to drive innovation. Timeline: Ongoing.
- Regulatory Approval in New Markets: Obtaining regulatory approval for its Antineoplastons in new geographic markets, such as Europe or Asia, could significantly expand the company's revenue potential. Each region has its own regulatory pathway, requiring specific clinical data and documentation. Timeline: 3-5 years.
- Development of New Antineoplaston Formulations: Developing new formulations of its Antineoplastons, such as oral or injectable versions, could improve patient convenience and compliance. This could also expand the potential applications of the drugs. The market for drug delivery technologies is growing rapidly. Timeline: 2-3 years.
- Increased Consulting Services: Expanding its consulting services related to antineoplaston therapies could generate additional revenue and strengthen the company's relationships with healthcare providers. The demand for specialized consulting services in the healthcare industry is increasing. Timeline: Ongoing.
Chancen
- Expansion of clinical trials to new cancer types.
- Strategic partnerships with larger pharmaceutical companies.
- Regulatory approval in new geographic markets.
- Development of new antineoplaston formulations.
Risiken
- Competition from established cancer therapies.
- Regulatory hurdles and uncertainty.
- Potential for adverse clinical trial results.
- Changes in healthcare regulations and reimbursement policies.
Wettbewerbsvorteile
- Proprietary Antineoplastons: The company's unique antineoplaston drugs represent a potential competitive advantage.
- Specialized Expertise: The company's expertise in antineoplaston therapies is a valuable asset.
- Established Brand: The Antineoplastons trade name has been in use for several years.
- Intellectual Property: Patents related to antineoplaston formulations and uses.
Ueber BZYR
Burzynski Research Institute, Inc., established in 1977 and based in Houston, Texas, is a biotechnology company dedicated to the research and development of antineoplaston drugs for cancer treatment. The company's core focus revolves around its proprietary Antineoplastons, which are medical chemical compounds composed of growth-inhibiting peptides, amino acid derivatives, and organic acids. These compounds are produced, marketed, and sold by the company. Since its inception, Burzynski Research Institute has been committed to exploring innovative approaches to cancer therapy. The company's activities encompass a range of services, including research, drug development, manufacturing, marketing, and consulting. Its primary product, Antineoplastons, represents a unique approach to cancer treatment, distinguishing it from conventional therapies. The company's operations are primarily based in the United States, with a focus on serving patients and healthcare providers seeking alternative cancer treatment options. Burzynski Research Institute also provides consulting services related to its antineoplaston therapies.
Was das Unternehmen tut
- Researches and develops antineoplaston drugs for cancer treatment.
- Produces medical chemical compounds composed of growth-inhibiting peptides.
- Markets and promotes its Antineoplastons trade name products.
- Sells its Antineoplastons products to patients and healthcare providers.
- Offers consulting services related to antineoplaston therapies.
- Focuses on alternative cancer treatment options.
Geschaeftsmodell
- Generates revenue through the sale of Antineoplastons.
- Provides consulting services to healthcare providers and patients.
- Invests in research and development of new antineoplaston therapies.
- Markets and promotes its products through various channels.
Branchenkontext
Burzynski Research Institute, Inc. operates within the biotechnology industry, a sector characterized by intense research and development, high regulatory hurdles, and significant competition. The company's focus on antineoplaston drugs places it in a niche market segment within the broader cancer therapeutics landscape. Competitors include companies like BETRF (Bio-Path Holdings, Inc.), BIXT (Bioxcel Therapeutics, Inc.), BVAXF (Blue Water Vaccines Inc), CPMV (CMP Pharma, Inc.), and FAMDF (Farmaceuticos Argentinos S.A.), all of which are pursuing different approaches to cancer treatment or related therapies. The biotechnology industry is driven by innovation and is subject to stringent regulatory oversight.
Wichtige Kunden
- Cancer patients seeking alternative treatment options.
- Healthcare providers interested in antineoplaston therapies.
- Research institutions involved in cancer research.
- Patients who have exhausted conventional cancer treatments.
Finanzdaten
Chart & Info
Burzynski Research Institute, Inc. (BZYR) Aktienkurs: Price data unavailable
Aktuelle Nachrichten
Keine aktuellen Nachrichten fuer BZYR verfuegbar.
Analystenkonsens
Konsens-Bewertung
Aggregierte Kauf-/Halten-/Verkauf-Empfehlungen von Benzinga, Yahoo Finance und Finnhub fuer BZYR.
Kursziele
Wall-Street-Kurszielanalyse fuer BZYR.
MoonshotScore
Was bedeutet diese Bewertung?
Der MoonshotScore bewertet das Wachstumspotenzial von BZYR auf einer Skala von 0-100 ueber mehrere Faktoren wie Innovation, Marktdisruption, finanzielle Gesundheit und Momentum.
Fuehrung: Stanislaw R. Burzynski
Founder and CEO
Stanislaw R. Burzynski is the founder and CEO of Burzynski Research Institute, Inc. He is a physician and scientist who has dedicated his career to researching and developing antineoplaston therapies for cancer. Dr. Burzynski received his medical degree from the Medical University of Lublin in Poland and later moved to the United States to continue his research. He has published numerous scientific papers on antineoplastons and their potential in cancer treatment.
Erfolgsbilanz: Under Dr. Burzynski's leadership, Burzynski Research Institute has developed and marketed Antineoplastons for cancer treatment. He has overseen the company's research and clinical trial programs. He has faced scrutiny and controversy regarding his methods, but has also garnered a dedicated following of patients seeking alternative cancer therapies.
BZYR OTC-Marktinformationen
The OTC Other tier represents the lowest tier of the OTC market, indicating that Burzynski Research Institute, Inc. may not meet the minimum financial standards or disclosure requirements for higher tiers like OTCQX or OTCQB. Companies in this tier may have limited information available to investors, and the trading of their stock can be highly speculative. Investing in OTC Other stocks carries significant risks compared to stocks listed on major exchanges like the NYSE or NASDAQ, due to less stringent regulatory oversight and reporting requirements.
- OTC-Stufe: OTC Other
- Offenlegungsstatus: Unknown
- Limited Disclosure: OTC Other companies often have minimal financial reporting requirements, making it difficult to assess their financial health.
- Low Liquidity: Trading volume is typically very low, leading to wide bid-ask spreads and potential price volatility.
- Regulatory Scrutiny: OTC stocks are subject to less regulatory oversight than exchange-listed stocks, increasing the risk of fraud or mismanagement.
- Going Concern Risk: Companies in the OTC Other tier may be facing financial difficulties or have a limited operating history.
- Information Asymmetry: Lack of readily available information can create an uneven playing field for investors.
- Verify the company's legal standing and registration.
- Review any available financial statements and disclosures.
- Assess the company's management team and their experience.
- Research the company's products or services and their market potential.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before investing.
- Check for any regulatory actions or legal proceedings against the company.
- Longevity of Operations: The company has been in operation since 1977.
- Focus on Research and Development: The company is actively involved in research and development of cancer therapies.
- Scientific Publications: The company has published scientific papers on antineoplastons.
- CEO with Medical Background: The CEO, Stanislaw R. Burzynski, is a physician and scientist.
- Dedicated Patient Following: The company has a dedicated following of patients seeking alternative cancer therapies.
Was Anleger ueber Burzynski Research Institute, Inc. (BZYR) wissen wollen
What are the key factors to evaluate for BZYR?
Burzynski Research Institute, Inc. (BZYR) currently holds an AI score of 42/100, indicating low score. Key strength: Unique antineoplaston therapies.. Primary risk to monitor: Potential: Competition from established cancer therapies and larger pharmaceutical companies.. This is not financial advice.
How frequently does BZYR data refresh on this page?
BZYR prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven BZYR's recent stock price performance?
Recent price movement in Burzynski Research Institute, Inc. (BZYR) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Unique antineoplaston therapies.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider BZYR overvalued or undervalued right now?
Determining whether Burzynski Research Institute, Inc. (BZYR) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying BZYR?
Before investing in Burzynski Research Institute, Inc. (BZYR), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding BZYR to a portfolio?
Potential reasons to consider Burzynski Research Institute, Inc. (BZYR) depend on individual investment goals and risk tolerance. A key strength identified by analysis: Unique antineoplaston therapies.. Additionally: Experienced leadership in cancer research.. Always weigh potential rewards against risks and diversify across holdings. This is not financial advice.
Can I buy fractional shares of BZYR?
Yes, most major brokerages offer fractional shares of Burzynski Research Institute, Inc. (BZYR) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track BZYR's earnings and financial reports?
Burzynski Research Institute, Inc. (BZYR) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Setting up alerts through your brokerage for BZYR earnings announcements is recommended.
Haftungsausschluss: Dieser Inhalt dient ausschliesslich zu Informationszwecken und stellt keine Anlageberatung dar. Fuehren Sie immer Ihre eigene Recherche durch und konsultieren Sie einen Finanzberater.
Offizielle Ressourcen
Daten dienen ausschliesslich zu Informationszwecken.
- Limited financial information is available for Burzynski Research Institute, Inc. due to its OTC market listing.
- Analyst coverage is not available for the company.
- The company's future prospects are subject to regulatory approval and clinical trial outcomes.